| Theme | Diagnosis and Treatment of Barrett's Esophagus : up-to-date | |
|---|---|---|
| Title | Surveillance of Barrett's Esophagus：Management with Medium- and Long-term Follow-ups | |
| Publish Date | 2014/06 | |
| Author | Jiro Watari | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Ken Hara | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Koichi Ikeo | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Shota Fukui | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Maki Kawanaka | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Toshihiko Tomita | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Tadayuki Oshima | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Hirokazu Fukui | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Hiroto Miwa | Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| [ Summary ] | Most Japanese patients with Barrett's esophagus (BE) exhibit BE < 1 cm in length, ultra-short BE, which is not included in the definition of BE in the West. BE-cancer risk may be associated with BE length. The annual incidence of BE-cancer in BE patients without dysplasia as observed through indexing biopsy, ranges from 0.33 % to 0.598 % per year based on meta-analyses. The cost-effectiveness of BE surveillance has recently been discussed because recent studies have shown that the annual incidence of BE related cancer is lower than that seen in previous studies. According to previous studies, surveillance of short-segment BE patients without dysplasia may not be needed in terms of cost-effectiveness. The establishment of biomarkers, indicating a high risk of BE-cancer and chemoprevention of BE is imperative. | |